Li et al. demonstrated that PD-L1 is heavily glycosylated in multiple cancer cell lines in response to activated EGFR that induces GSK3β phosphorylation, leading to inhibition of the binding of GSK3β to PD-L1. The gene discussed is GSK3B; the disease is cancer.